Downloads
-
Building A Biotech Hub With Intellia Therapeutics' John Leonard, M.D.
1/14/2024
We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO at Intellia Therapeutics. In addition to how he’s built late-clinical stage Intellia, Dr. Leonard shares the foundational elements of a biotech community, particularly around rapidly-advancing technologies such as CRISPR, and what biotech ecosystems offer emerging biotechs in terms of resources, intellectual property, and support.
-
Finding New Treatments In Old Therapies
1/12/2024
Discover the types of repurposed drugs and tips for making them a reality with international healthcare consultant Robert L. Quigley, MD, D.Phil.
-
A Patient-Centric Approach Built On The Porosome
1/10/2024
About 85% of disease-causing proteins remain impervious to current therapeutic interventions. One potential pathway to address this problem is the structure in the cell that constitutes its secretory machinery: the porosome.
-
Animal Testing Isn’t Perfect. Is There An Alternative?
1/8/2024
Statistics have been showing that rodent and non-rodent experiments predict human toxicity in only 48-71% of drugs. The FDA Modernization Act 2.0 of 2022 permits the use of suitable animal-free new approach methodologies, and the European Parliament launched a program to eliminate animal studies "as soon as scientifically possible." Let's take a data-driven, research-driven look at the topic.
-
Art Of The Pivot With Elevation Oncology's Joe Ferra
1/7/2024
Relatively new CEO Joseph Ferra has orchestrated some pretty significant change at Elevation Oncology in the two(ish) years since the Business of Biotech last hosted the company. In that short time, Ferra advanced from CFO to CEO, a move that aligned very closely with the company's difficult decision to shelve the late phase 2 anti-HER3 monoclonal antibody candidate it was founded on.
-
AI In Drug Discovery And Development — Will It Live Up To The Hype?
1/5/2024
While AI may soon transform the drug discovery and development process, there are still several barriers, both technical and ethical, to the rise of AI in biopharma.
-
4 Keys To Allo In 2024 With Poseida Therapeutics' Kristin Yarema, Ph.D.
1/4/2024
Kristin Yarema, Ph.D., CEO, Poseida Therapeutics sits down with Cell & Gene: The Podcast Host Erin Harris to discuss four of the biggest challenges the CGT sector faces when it comes to the development of off-the-shelf therapies. Kristin shares how 2024 might see some real progress in allogeneic therapies.
-
CDMO Collab with Scorpius BioManufacturing's Steve Lavezoli + Fina Biosolutions' Dr. Andrew Lees
12/27/2023
A new year marks a fresh start for biotech partnerships, and to kick off 2024, we're highlighting a good one. Fina Biosolutions' Dr. Andrew Lees recently signed on with Scorpius BioManufacturing to support his company's growth plan. On Business of Biotech, Lees sits down with Scorpius VP of commercial operations Steve Lavezoli for a frank conversation on the ups, downs, and expectations of a biotech + CDMO relationship. If you're considering signing on with an outsourced manufacturing partner, or thinking about making a switch, you won't want to miss this episode.
-
Lowering The Lipids Barrier: The Key To Accelerating RNA-LNP Drug Development
12/27/2023
Learn about the drug development hurdles that must be overcome to deliver on the promise of mRNA.
-
Cell Therapy For Corneal Endothelial Dystrophies
12/21/2023
A first-time attendee of Meeting on the Mesa discusses his experience and delves into the cell therapy used to treat corneal endothelial disease.